Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

Kaos Capital, a Miami-based activist hedge fund, announced it has acquired 4.9% of BioRestorative Therapies (NASDAQ:BRTX) through open-market purchases.

Rhea-AI Summary

Kaos Capital, a Miami-based activist hedge fund, announced it has acquired 4.9% of BioRestorative Therapies (NASDAQ:BRTX) through open-market purchases. Kaos Capital believes BRTX could benefit from a strategic review and a potential pivot into AI opportunities to better unlock shareholder value.

Positive

• Kaos Capital acquires 4.9% ownership stake in BRTX via open-market purchases
• Activist investor signals willingness to work constructively with the BRTX board and management
• Potential strategic review and AI pivot proposed as paths to enhance shareholder value

Negative

• Kaos Capital believes BRTX shareholders are not gaining meaningful value from the existing business
• Proposed strategic review and AI pivot introduce uncertainty around current strategy for investors

Argus May 27 session

+73.30% close to close Open Argus

Details

News Market Reaction – BRTX

On May 27, the day this news came out, BRTX closed 73.30% above the previous close.

Data tracked by StockTitan Argus for the May 27 session.

Market Context

On May 27, the day this news came out, the stock closed 73.3% above the previous close. A strong pos...

Analysis

On May 27, the day this news came out, the stock closed 73.3% above the previous close. A strong positive reaction aligns with the stock’s recent sensitivity to catalysts, as seen with the +20.1% move following Phase 2 dosing news. An activist acquiring 4.9% can focus attention on strategy and capital allocation, which may resonate given going‑concern language and dilution risk from increasing authorized shares to 1.5B. However, prior events show that enthusiasm around good news has sometimes faded quickly, so sustainability has been inconsistent.

Key Figures

Kaos Capital stake: 4.9% of common stock Q1 2026 revenue: $23,170 Q1 2026 net loss: $2.15M +5 more

Kaos Capital stake

4.9% of common stock

Ownership acquired in open-market purchases as disclosed in article

Q1 2026 revenue

$23,170

First‑quarter 2026 revenue, similar to prior year’s $25,000

Q1 2026 net loss

$2.15M

Narrowed from $5.34M net loss a year earlier

Cash and equivalents

$3.11M cash, $0.48M securities

Balances at March 31, 2026 per 10-Q

Going concern warning

Substantial doubt disclosed

Management cites recurring losses and negative operating cash flow

Nasdaq bid noncompliance

$1.00 minimum bid

Nasdaq notice on March 26, 2026 for bid-price deficiency

Authorized share increase

75,000,000 to 1,500,000,000

Proposed common share authorization increase in proxy materials

Auctus ownership

2,699,470 shares (9.9%)

Schedule 13G/A beneficial ownership including warrants

Historical Context

5 past events · Latest: May 26

5 events

1. May 26

   Phase 2 dosing complete

   24h Move

   +20.1%

   Completed dosing of 99 patients in BRTX-100 Phase 2 with Fast Track status.

2. May 13

   Preclinical data update

   24h Move

   -5.8%

   Presented new exosome and EV preclinical data for BioCosmeceutical applications.

3. May 07

   Phase 2 blinded data

   24h Move

   -8.1%

   Reported sustained pain and function improvements in BRTX-100 blinded Phase 2 dataset.

4. Apr 30

   Conference presentation

   24h Move

   +11.6%

   Announced upcoming ISCT 2026 presentations on Phase 2 trial and BioCosmeceutical platform.

5. Apr 21

   Dermatology partnership

   24h Move

   -7.8%

   Formed strategic partnership with Dr. Goldberg to clinically evaluate BioCosmeceuticals.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

activist investing

1 terms

activist investing financial

"Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced..."

A style of investing where individuals or funds buy a meaningful stake in a company and actively push for changes—such as replacing leadership, reshaping strategy, cutting costs, or returning cash to shareholders—to try to increase the company’s value. Think of it like a neighbor who buys into a shared building and then campaigns for renovations; for other investors this can speed up value-creating moves but also bring short-term volatility and management conflict that affect stock price and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders

MIAMI, May 27, 2026 /PRNewswire/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. ("BRTX" or the "Company").

This ownership stake was acquired in the open market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle may be better positioned for a strategic pivot into the AI space.

Unfortunately, BRTX shareholders are not currently gaining meaningful value from the existing business. We at Kaos feel that the Company should explore a comprehensive strategic review and consider a pivot into a broader range of AI opportunities.

As a significant shareholder, Kaos Capital is committed to working constructively with the BRTX Board of Directors and management to unlock shareholder value. To that end, we intend to seek an immediate meeting with the Board to discuss the Company's strategy, operations, corporate governance, and potential pathways—including a possible pivot into AI—to enhance value for all shareholders.

We look forward to engaging in a productive dialogue that prioritizes the best interests of BRTX and its shareholders.

About Kaos Capital

Kaos Capital Ltd. is a Miami-based hedge fund with offices in The Bahamas and Toronto, specializing in activist investing, primarily in the Canadian and U.S. markets. Led by Adam Arviv, Kaos Capital seeks to partner with management teams and boards to drive operational improvements and strategic initiatives that maximize long-term shareholder value.

Cautionary Note

This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. All investments involve risk, and past performance is not indicative of future results. Shareholders should consult their own advisors regarding their individual circumstances.

View original content:https://www.prnewswire.com/news-releases/kaos-capital-announces-acquisition-of-4-9-stake-in-biorestorative-therapies-nasdaq-brtx-302782386.html

SOURCE KAOS Capital

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake did Kaos Capital acquire in BioRestorative Therapies (NASDAQ:BRTX) in May 2026?

Kaos Capital acquired a 4.9% stake in BioRestorative Therapies. According to Kaos Capital, this position was built through normal-course open-market stock purchases and makes the hedge fund a significant shareholder in BRTX.

Why does Kaos Capital view BioRestorative Therapies (BRTX) as an opportunity?

Kaos Capital views BRTX as a compelling opportunity for value creation. According to Kaos Capital, the public company structure may be better positioned for a strategic pivot into a broader range of artificial intelligence opportunities.

What strategic changes is Kaos Capital proposing for BioRestorative Therapies (BRTX)?

Kaos Capital is urging a comprehensive strategic review and considering a pivot into AI. According to Kaos Capital, exploring broader AI opportunities could help unlock greater value for BRTX shareholders than the current business focus.

How does Kaos Capital plan to engage with the BioRestorative Therapies (BRTX) board?

Kaos Capital plans to seek an immediate meeting with the BRTX board. According to Kaos Capital, discussions would cover strategy, operations, corporate governance, and potential AI-related pathways to enhance long-term shareholder value.

What concerns does Kaos Capital raise about current shareholder value at BioRestorative Therapies (BRTX)?

Kaos Capital believes BRTX shareholders are not receiving meaningful value from the existing business. According to Kaos Capital, this underpins its call for a strategic review and exploration of AI-focused opportunities to improve outcomes.

Is Kaos Capital taking a hostile approach toward BioRestorative Therapies (BRTX)?

Kaos Capital emphasizes a constructive approach with the BRTX board and management. According to Kaos Capital, it seeks productive dialogue aimed at strategies that prioritize the best interests of BioRestorative Therapies and all shareholders.